跳至主要内容
临床试验/CTRI/2020/05/025319
CTRI/2020/05/025319招募中3 期

Angiotensin Receptor Blocker Losartan for prevention of COVID 19 complications: a randomized placebo controlled trial - LICCI

Sanjay gandhi Post Graduate Institute of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Age > 18 years
  • 2. Requirement of hospitalization
  • 3. Randomization within 24 hours of initial presentation to a hospital/diagnosis

排除标准

  • 1. Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB)
  • 2. Prior reaction or intolerance to an ARB or ACEi
  • 3. Blood pressure less than 100/70 mmHg
  • 4. Potassium great than 5.0 mEq/L
  • 5. Pregnancy or breastfeeding In females of childbearing age, unwillingness to use birth control for the duration of the study
  • 6. Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2
  • 7. AST and/or ALT > 3 times the upper limit of normal
  • 8. Severe volume depletion or severe acute kidney injury that, in the opinion of the investigator, would preclude administration of Losartan
  • 9. Concurrent treatment
  • 10. Inability to obtain informed consent
  • 11. Pregnancy

研究者

相似试验